Cardio-oncology in targeting the HER receptor family: The puzzle of different cardiotoxicities of HER2 inhibitors

Future Cardiology

Volumn 7, Issue 5, 2011, Pages 693-704

  Albini, Adriana ^a   Cesana, Eugenio ^a   Donatelli, Francesco ^a,b   Cammarota, Rosaria ^a   Bucci, Eraldo O ^a   Baravelli, Massimo ^a   Anzà, Claudio ^a   Noonan, Douglas M ^c  

^a IRCCS MULTIMEDICA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

cardio oncology; cardiotoxicity; HER receptors; lapatinib; prevention; trastuzumab

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; GEFITINIB; LAPATINIB; LETROZOLE; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; RAZOXANE; TRASTUZUMAB; TROPONIN I;

ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE FREE SURVIVAL; FEVER; HEAD AND NECK CARCINOMA; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RASH; REVIEW; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEART; HUMANS; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RAZOXANE; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 80053095476     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.11.54     Document Type: Review

References (88)

1. Casalini P, Iorio MV, Galmozzi E et al. Role of HER receptors family in development and differentiation. J. Cell. Physiol. 200(3), 343-350 (2004). (Pubitemid 39006925)
2. Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int. J. Radiat. Oncol. Biol. Phys. 58(3), 903-913 (2004). (Pubitemid 38221150)
3. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2(2), 127-137 (2001). (Pubitemid 33674041)
4. Gassmann M, Casagranda F, Orioli D et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378(6555), 390-394 (1995).
5. Lee KF, Simon H, Chen H et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378(6555), 394-398 (1995).
6. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature 378(6555), 386-390 (1995).
7. Dahabreh IJ, Terasawa T, Castaldi PJ et al. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann. Intern. Med. 154(1), 37-49 (2011).
8. Baynes RD, Gansert J. KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer. Am. J. Ther. 16(6), 554-561 (2009).
9. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26(35), 5705-5712 (2008).
10. Siena S, Sartore-Bianchi A, Di Nicolantonio F et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl Cancer Inst. 101(19), 1308-1324 (2009).
11. Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin. Ther. 32(3), 437-453 (2010).
12. Zambelli A, Della Porta MG, Eleuteri E et al. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. Breast 20(2), 176-183 (2011).
13. Benz CC, Scott GK, Sarup JC et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat. 24(2), 85-95 (1992). (Pubitemid 23063891)
14. Yang H, Zhao R, Yang HY et al. Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity. Oncogene 24(11), 1924-1935 (2005). (Pubitemid 40467584)
15. Borg A, Baldetorp B, Ferno M et al. ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6(1), 137-143 (1991). (Pubitemid 21923993)
16. Fendly BM, Kotts C, Vetterlein D et al. The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. J. Biol. Response Mod. 9(5), 449-455 (1990). (Pubitemid 20366157)
17. Carter P, Presta L, Gorman CM et al. Humanization of an anti-p185 HER2 antibody for human cancer therapy. Proc. Natl Acad. Sci. USA 89(10), 4285-4289 (1992).
18. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001). (Pubitemid 32222155)
19. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354(8), 809-820 (2006). (Pubitemid 43290919)
20. Carver JR. Management of trastuzumab-related cardiac dysfunction. Prog. Cardiovasc. Dis. 53(2), 130-139 (2010).
21. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357(1), 39-51 (2007). (Pubitemid 47026733)
22. Izumi Y, Xu L, di Tomaso E et al. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416(6878), 279-280 (2002). (Pubitemid 34260234)
23. Gennari R, Menard S, Fagnoni F et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res. 10(17), 5650-5655 (2004). (Pubitemid 39180938)
24. Mouridsen H, Keshaviah A, Coates AS et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J. Clin. Oncol. 25(36), 5715-5722 (2007).
25. Molteni LP, Rampinelli I, Cergnul M et al. Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment. Breast J. 16(Suppl. 1) S45-S48 (2010).
26. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9(7), 463-475 (2009).
27. Jathal MK, Chen L, Mudryj M et al. Targeting ErbB3: the New RTK(id) on the prostate cancer block. Immunol. Endocr. Metab. Agents Med. Chem. 11(2), 131-149 (2011).
28. Langdon SP, Faratian D, Nagumo Y et al. Pertuzumab for the treatment of ovarian cancer. Expert Opin. Biol. Ther. 10(7), 1113-1120 (2010).
29. Albini A, Pennesi G, Donatelli F et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J. Natl Cancer Inst. 102(1), 14-25 (2010).
30. Gennari A, Sormani MP, Pronzato P et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J. Natl Cancer Inst. 100(1), 14-20 (2008). (Pubitemid 351767337)
31. Bria E, Cuppone F, Milella M et al. Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues. Expert Opin. Biol. Ther. 8(12), 1963-1971 (2008).
32. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol. 53(24), 2231-2247 (2009).
33. Curigliano G, Mayer EL, Burstein HJ et al. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog. Cardiovasc. Dis. 53(2), 94-104 (2010).
34. Costa RB, Kurra G, Greenberg L et al. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann. Oncol. 21(11), 2153-2160 (2010).
35. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J. Clin. Oncol. 23(13), 2900-2902 (2005). (Pubitemid 46224107)
36. Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol. 23(31), 7820-7826 (2005). (Pubitemid 46657379)
37. Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J. Clin. Oncol. 26(8), 1201-1203 (2008).
38. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17(9), 2639-2648 (1999). (Pubitemid 29415219)
39. Negro A, Brar BK, Lee KF. Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog. Horm. Res. 59, 1-12 (2004). (Pubitemid 41327144)
40. Spector NL, Yarden Y, Smith B et al. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc. Natl Acad. Sci. USA 104(25), 10607-10612 (2007). (Pubitemid 47185712)
41. Gordon LI, Burke MA, Singh AT et al. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J. Biol. Chem. 284(4), 2080-2087 (2009).
42. Crone SA, Zhao YY, Fan L et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8(5), 459-465 (2002). (Pubitemid 34546747)
43. Ozcelik C, Erdmann B, Pilz B et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl Acad. Sci. USA 99(13), 8880-8885 (2002). (Pubitemid 34693652)
44. Hedhli N, Russell KS. Cytostatic drugs, neuregulin activation of erbB receptors, and angiogenesis. Curr. Hypertens. Rep. 12(6), 411-417 (2010).
45. Rochais F, Fischmeister R. Acute cardiac effects of neuregulin-1/ErbB signalling. Cardiovasc. Res. 88(3), 393-394 (2010).
46. Azim H, Azim HA Jr, Escudier B. Trastuzumab versus lapatinib: the cardiac side of the story. Cancer Treat. Rev. 35(7), 633-638 (2009).
47. Grazette LP, Boecker W, Matsui T et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J. Am. Coll. Cardiol. 44(11), 2231-2238 (2004). (Pubitemid 39576044)
48. Pentassuglia L, Graf M, Lane H et al. Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Exp. Cell Res. 315(7), 1302-1312 (2009).
49. Pentassuglia L, Timolati F, Seifriz F et al. Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes. Exp. Cell Res. 313(8), 1588-1601 (2007). (Pubitemid 46589436)
50. Spallarossa P, Altieri P, Pronzato P et al. Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane. J. Pharmacol. Exp. Ther. 332(1), 87-96 (2010).
51. Giampaglia M, Chiuri VE, Tinelli A et al. Lapatinib in breast cancer: clinical experiences and future perspectives. Cancer Treat. Rev. 36(Suppl. 3) S72-S79 (2010).
52. Perez EA, Koehler M, Byrne J et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin. Proc. 83(6), 679-686 (2008). (Pubitemid 351810568)
53. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006). (Pubitemid 46021510)
54. Hasinoff BB, Patel D. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Toxicol. Appl. Pharmacol. 249(2), 132-139 (2010).
55. Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ. Res. 106(1), 21-34 (2010).
56. Gordon MS, Matei D, Aghajanian C et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J. Clin. Oncol. 24(26), 4324-4332 (2006). (Pubitemid 46630791)
57. Agus DB, Sweeney CJ, Morris MJ et al. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J. Clin. Oncol. 25(6), 675-681 (2007). (Pubitemid 350002923)
58. Herbst RS, Davies AM, Natale RB et al. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin. Cancer Res. 13(20), 6175-6181 (2007). (Pubitemid 350075078)
59. Shell SA, Lyass L, Trusk PB et al. Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells. Cell Cycle 7(12), 1769-1775 (2008). (Pubitemid 351988742)
60. Monsuez JJ, Charniot JC, Vignat N et al. Cardiac side-effects of cancer chemotherapy. Int. J. Cardiol. 144(1), 3-15 (2010).
61. Jensen BV. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Semin Oncol. 33(3 Suppl. 8), S15-S21 (2006).
62. Menna P, Salvatorelli E, Minotti G. Cardiotoxicity of antitumor drugs. Chem. Res. Toxicol. 21(5), 978-989 (2008).
63. Maejima Y, Adachi S, Ito H et al. Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage. Aging Cell 7(2), 125-136 (2008). (Pubitemid 351359646)
64. Gabrielson K, Bedja D, Pin S et al. Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury. Cancer Res. 67(4), 1436-1441 (2007). (Pubitemid 46383368)
65. Cardinale D, Colombo A, Torrisi R et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J. Clin. Oncol. 28(25), 3910-3916 (2010).
66. Goel S, Beith JM. Troponin I as a predictor for trastuzumab-related cardiotoxicity: current data do not provide mechanistic insights or allow for incorporation into clinical practice. J. Clin. Oncol. 29(7), e175-e176 (2011).
67. Morris PG, Chen C, Steingart RM et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin. Cancer Res. 17(10), 3490-3499 (2011).
68. Testore F, Milanese S, Ceste M et al. Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10 year single institution experience. Am. J. Cardiovasc. Drugs 8(4), 257-263 (2008).
69. Wiseman LR, Spencer CM. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs 56(3), 385-403 (1998). (Pubitemid 28454265)
70. Malisza KL, Hasinoff BB. Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells. Free Radic. Biol. Med. 20(7), 905-914 (1996). (Pubitemid 26157506)
71. Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J. Cancer Res. Clin. Oncol. 130(1), 1-7 (2004). (Pubitemid 38161241)
72. Walker JR, Sharma A, Lytwyn M et al. The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity. J. Am. Soc. Echocardiogr. 24(6), 699-705 (2011).
73. Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114(23), 2474-2481 (2006). (Pubitemid 44901520)
74. Ferrari N, Tosetti F, De Flora S et al. Diet-derived phytochemicals: from cancer chemoprevention to cardio-oncological prevention. Curr. Drug Targets (2011) (Epub ahead of print).
75. Tosetti F, Noonan DM, Albini A. Metabolic regulation and redox activity as mechanisms for angioprevention by dietary phytochemicals. Int. J. Cancer 125(9), 1997-2003 (2009).
76. Zhang C, Feng Y, Qu S et al. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc. Res. 90(3), 538-545 (2011).
77. Chen T, Xu T, Li Y et al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat. Rev. 37(4), 312-320 (2011).
78. Martin M, Sanchez-Rovira P, Munoz M et al. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-2005 study. Ann. Oncol. DOI: 10.1093/annonc/mdr024 (2011) (Epub ahead of print).
79. Di Leo A, Gomez HL, Aziz Z et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J. Clin. Oncol. 26(34), 5544-5552 (2008).
80. Burris HA 3rd. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 9(Suppl. 3) 10-15 (2004).
81. Higa GM, Abraham J. Lapatinib in the treatment of breast cancer. Expert Rev. Anticancer Ther. 7(9), 1183-1192 (2007). (Pubitemid 47521015)
82. Minkovsky N, Berezov A. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr. Opin. Investig. Drugs 9(12), 1336-1346 (2008).
83. de Bono JS, Bellmunt J, Attard G et al. Open-label Phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J. Clin. Oncol. 25(3), 257-262 (2007). (Pubitemid 350003013)
84. Rabindran SK, Discafani CM, Rosfjord EC et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 64(11), 3958-3965 (2004). (Pubitemid 38697310)
85. Minami Y, Shimamura T, Shah K et al. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene 26(34), 5023-5027 (2007). (Pubitemid 47172642)
86. Krop IE, Beeram M, Modi S et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 28(16), 2698-2704 (2010).
87. Jumbe NL, Xin Y, Leipold DD et al. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J. Pharmacokinet. Pharmacodyn. 37(3), 221-242 (2010).
88. Junttila TT, Li G, Parsons K et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res. Treat. 128(2), 347-356 (2011).